Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Aug
9
2021
California Breaks New Ground With OCal: Answers to Key Questions About “Comparable-to-Organic” Cannabis Sheppard, Mullin, Richter & Hampton LLP
Nov
6
2013
Supreme Court Grants Limited Review of Greenhouse Gas Emissions Regulations Sheppard, Mullin, Richter & Hampton LLP
Feb
16
2022
Restructure This! Episode 3: Canada: Cannabis Boom or Bust? [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
Mar
1
2022
Treasury Department Recommends Antitrust Reform in Alcohol Markets Sheppard, Mullin, Richter & Hampton LLP
Mar
18
2022
OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2019
Second Circuit Affirms “Snap” Removal Practice Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2022
International Cooperation under China’s Proposed Implementing Rules for Human Genetic Resources Management Sheppard, Mullin, Richter & Hampton LLP
Jun
20
2022
Supreme Court Saves Hospitals from $1.6B Cut to 340B Program Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2022
FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET® Sheppard, Mullin, Richter & Hampton LLP
Oct
5
2022
Takeaways From the U.S. Patent and Trademark Office’s Artificial Intelligence and Emerging Technologies Partnership Series – Part Two of Three Sheppard, Mullin, Richter & Hampton LLP
Feb
14
2023
FDA Issues Warning Letter to RightEye, LLC For Misbranding and Adulteration Sheppard, Mullin, Richter & Hampton LLP
Apr
10
2023
FDA To Require Demonstration of Cybersecurity Safeguards for Pre-Market Submissions of Certain Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Jan
14
2020
Day 1 Notes at the 2020 J.P. Morgan Healthcare Conference Sheppard, Mullin, Richter & Hampton LLP
Jun
4
2023
FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023 Sheppard, Mullin, Richter & Hampton LLP
Feb
28
2020
Federal Circuit Changes the Game for Selling Single-API Drugs to the Government Sheppard, Mullin, Richter & Hampton LLP
Jun
11
2023
Is this “Good-Bye” to the Two-Year Mandatory Minimum in Healthcare Fraud Cases? Sheppard, Mullin, Richter & Hampton LLP
Apr
4
2016
Second Circuit Narrowly Applies Supreme Court’s Decision in Omnicare Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2023
Healthier Choices Management Corp. v. Philip Morris USA, Inc. No. 22-1268 (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
Apr
6
2020
CMS “Hospitals Without Walls” Waiver: Looking To ASCs to Provide Relief Sheppard, Mullin, Richter & Hampton LLP
Aug
17
2023
Fifth Circuit Rules to Reinstate Abortion Pill Restrictions Sheppard, Mullin, Richter & Hampton LLP
Oct
9
2023
At HLTH 2023: General Catalyst’s HATCo Introduces a Radically Ambitious and Transformative Model for Healthcare Sheppard, Mullin, Richter & Hampton LLP
May
15
2020
Not So Fast – FDA Retracts Authorization for Some Respirators Made in China Sheppard, Mullin, Richter & Hampton LLP
Jan
2
2024
The Intertwining Nature of Motivation to Combine and Reasonable Expectation of Success Sheppard, Mullin, Richter & Hampton LLP
Jan
29
2024
2024 Top-of-Mind Issues for Life Sciences Companies Sheppard, Mullin, Richter & Hampton LLP
Feb
6
2024
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® Sheppard, Mullin, Richter & Hampton LLP
Feb
20
2024
New Bills Being Served Up That May Soon Impact Food Retailers and Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2020
A Year of Living Dangerously: 2020 and Maneuvers on the 340B Drug Pricing Program Battlefield Sheppard, Mullin, Richter & Hampton LLP
Mar
19
2024
Time to Refresh? FDA Issues Draft Guidance on Key Information and Informed Consent Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins